Immunoblotting of tumor lysates revealed that PVRL4 antibody treatment resulted in a precipitous decline of PVRL4 protein levels, suggesting that cells with the highest expression of PVRL4 were eliminated by the treatment (Figure 7E). The gene discussed is NECTIN4; the disease is neoplasm.